Context Therapeutics Inc (CNTX) FinancialsCNTXContext Therapeutics Inc

Evaluating the bottom line, Context Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -76.14%, provide a clear picture of how effectively CNTX converts its operational activities into shareholder value.

In the context of the broader market, CNTX competes directly with industry leaders such as LITS and KYNB. With a market capitalization of $35.25M, it holds a leading position in the sector. When comparing efficiency, CNTX's gross margin of N/A stands against LITS's N/A and KYNB's -81.45%. Such benchmarking helps identify whether Context Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $14.56 million in Q2 2026, with a diluted EPS of -0.15, reflecting ongoing financial struggles. The current ratio has decreased significantly to 5.81, indicating potential liquidity concerns.